No information
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Phimosis |
|---|
|
| Steroid-sensitive dermatoses |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information available on dose adjustment in renal impairment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
The risk of systemic effects is greatest when: used on children, used under occlusion, used on large areas of skin or skin folds, and used simultaneously with penetration-enhancing medicines (such as salicylic acid, urea, propylene glycol).
In children, the secretion of growth hormone can be suppressed. No systemic or local side effects were reported when using clobetasol in phimosis.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Be cautious when using on children (relatively large skin surface area and thin skin), due to the increased risk of systemic side effects. Prolonged use of particularly potent dermatocorticosteroids in children can lead more quickly to adrenal suppression and also to growth hormone suppression; during prolonged use, it is recommended to regularly monitor height and weight and to determine plasma cortisol levels.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Corticosteroids, weak (group I) | ||
|---|---|---|
| D07AA02 | ||
| Corticosteroids, moderately potent (group II) | ||
|---|---|---|
| D07AB01 | ||
| D07AB02 | ||
| D07AB09 | ||
| Corticosteroids, potent (group III) | ||
|---|---|---|
| D07AC01 | ||
| D07AC03 | ||
| D07AC17 | ||
| D07AC14 | ||
| D07AC13 | ||
| D07AC18 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.